SCHEMBL770698

SCHEMBL770698

Cc1ccc(-c2nccn2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
HTT P42858 3/20 0.49
POLB P06746 1/20 0.49
ALDH3A1 P30838 1/20 0.49
NOD1 Q9Y239 1/20 0.49
RAPGEF4 Q8WZA2 1/20 0.48
HTR6 P50406 6/20 0.47
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
MET P08581 1/20 0.47
CYP2C19 P33261 1/20 0.47
GAA P10253 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
ALDH1A1 P00352 3/20 0.42
TSHR P16473 2/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
HTR7 P34969 1/20 0.42
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28303263 0.94 L3MBTL1 (0.54) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL723626 0.90 MET (0.51) L3MBTL1HTTHTR6NR1H2NR1H3
SCHEMBL18040300 0.86 ALDH3A1 (0.48) HTTALDH3A1HTR6METCYP2C19
SCHEMBL15902658 0.86 MEN1 (0.47) L3MBTL1HTTHTR6METCYP2C19
SCHEMBL724292 0.86 PKM (0.49) HTTALDH3A1RAPGEF4HTR6NR1H2
SCHEMBL18040302 0.85 MEN1 (0.51) L3MBTL1HTTPOLBRAPGEF4HTR6
SCHEMBL18040298 0.82 HTR6 (0.46) L3MBTL1NOD1HTR6METCYP2C19
SCHEMBL724342 0.81 KMT2A (0.51) HTTPOLBNOD1HTR6MET
SCHEMBL9089850 0.81 L3MBTL1 (0.48) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL28219756 0.80 PKM (0.52) ALDH3A1RAPGEF4HTR6NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
US-10865196-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2020-12-15 US disclosed
US-10301285-B2 Compounds for treatment of cancer GTX, INC. (US) 2019-05-28 US disclosed
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2019-03-28 US disclosed
EP-2608671-B1 COMPOUNDS FOR TREATMENT OF CANCER GTX INC (US) 2018-12-12 EP disclosed
US-10022356-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2018-07-17 US disclosed
US-20160015688-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-01-21 US disclosed
EP-2964028-A1 COMPOUNDS FOR TREATMENT OF CANCER University of Tennessee Research Foundation (US) 2016-01-13 EP disclosed
US-9029408-B2 Compounds for treatment of cancer GTX, INC. (US) 2015-05-12 US disclosed
WO-2014138279-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2014-09-12 WO disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 US disclosed
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2014-07-31 US disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-10865196-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 L3MBTL1 2834/4885HTT 4306/4885POLB 740/4885
US-20160015688-A1 COMPOUNDS FOR TREATMENT OF CANCER BRAF, NRAS, RAF1 L3MBTL1 2246/4885HTT 2637/4885POLB 690/4885
US-10301285-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 L3MBTL1 2834/4885HTT 4306/4885POLB 740/4885
US-10022356-B2 Compounds for treatment of cancer BRAF, NRAS, RAF1 L3MBTL1 2246/4885HTT 2637/4885POLB 690/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 L3MBTL1 2834/4885HTT 4306/4885POLB 740/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 L3MBTL1 2834/4885HTT 4306/4885POLB 740/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 L3MBTL1 1039/4885HTT 4461/4885POLB 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.